DekaBank Deutsche Girozentrale Sells 7,929 Shares of IQVIA Holdings Inc. (NYSE:IQV)

DekaBank Deutsche Girozentrale lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 190,719 shares of the medical research company's stock after selling 7,929 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.11% of IQVIA worth $33,479,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. American National Bank & Trust bought a new stake in shares of IQVIA in the first quarter valued at approximately $26,000. Golden State Wealth Management LLC increased its holdings in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the period. ST Germain D J Co. Inc. raised its position in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the 4th quarter worth about $39,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IQV. Barclays cut their price target on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and lowered their target price for the company from $260.00 to $160.00 in a report on Friday, April 25th. Truist Financial reduced their price target on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Finally, Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Stock Performance

NYSE:IQV traded down $2.80 during trading hours on Friday, reaching $162.73. The company had a trading volume of 1,156,699 shares, compared to its average volume of 1,660,352. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The firm has a market cap of $28.15 billion, a price-to-earnings ratio of 22.17, a PEG ratio of 1.81 and a beta of 1.30. The firm's 50 day moving average price is $151.96 and its 200-day moving average price is $171.78.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The company's revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the company posted $2.54 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.